logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
21/06/2025
According to reports, Mitsubishi Corporation will invest $3.9 billion in the solar energy sector in the United States.
Latest
6 m ago
Shenzhen Energy and Huawei collaborate on developing a new energy meteorological power forecasting large model.
12 m ago
When asked about the news of the rumored sale of Maserati, a spokesperson for Stellantis said, "Forgive me for being blunt, but Maserati is not for sale."
17 m ago
Micron Technology (MU.US) announces upcoming financial results and receives target price upgrade from Wedbush.
17 m ago
On June 21, according to the Novo Nordisk website, Novo Nordisk announced the results of the Phase 3b STEPUP trial for non-diabetic obese patients at the American Diabetes Association (ADA) scientific meeting in Chicago. The data showed that during the 72-week treatment period, higher doses of Wegovy (semaglutide 7.2mg) led to an average weight loss of 21% in obese patients compared to placebo, with one-third of participants achieving a weight loss of 25% or more. The safety and tolerability of the higher dose of Wegovy (7.2mg) was consistent with the 2.4mg dose.
21 m ago
The new augmented reality program can assist users in independently completing professional tasks.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.